April 27, 2021    London, UK

Webinar on Genetic and Stem Cell Therapy


Advancements in stem cell therapy continue to shed light on how stem cells may be used in various clinical applications, which include cell replacement therapies, immunomodulatory therapies, and many others. Whether you’re developing an induced pluripotent stem cell therapy or adult stem cell therapy, Thermo Fisher Scientific has the solutions to advance your research to the clinic and beyond. Advancing your stem cell therapy research to clinical treatment requires careful material selection because the quality of starting materials significantly impacts the properties of your final stem cell therapy product. We offer high-quality products for a variety of stem cell types.

Gene Therapy covers both the research and clinical applications of the new gene therapy techniques currently being developed. The application of molecular biology has revolutionized our understanding of many diseases and has been readily applied for diagnostic purposes.

Mesenchymal stem cells (MSC) are known to be multipotent, which are only seen in adult tissues like  in the muscle, liver, bone marrow. Mesenchymal stem cells usually function as structural support in various organs as mentioned above, and control the movement of substances. MSC can differentiate into various cell categories as an instance of adipocytes, osteocytes, and chondrocytes, derived by the mesodermal layer. Whereas the mesoderm layer provides an increase to the body’s skeletal elements, such as relating to the cartilage or bone. These are well-known to be essential for regenerative medicine. Since they are easily isolated and obtain high yield, high plasticity, which makes able to facilitate inflammation and encourage cell growth, cell differentiation, and restoring tissue.

Human Pluripotent Stem Cells (hPSCs) are characterized by their capacity to self-renew and separate into any cell type of the human body. To fully utilize potential of hPSCs for translational research and clinical applications, it is critical to develop rigorous cell separation protocols under feeder-free conditions that are efficient, reproducible, and versatile for high-throughput projects. Focusing on neural change of hPSCs, here we describe robust small molecule-based procedures that generate neural stem cells (NSCs) in less than seven days under chemically defined conditions. These protocols can be utilized to dissect the mechanisms of neural lineage entry and to further develop systematic protocols that produce the cellular diversity of the central nervous system at industrial scale. The most notable type of Pluripotent stem cells is the embryonic stem cell. However, since the generation of embryonic stem cells involves destruction of the pre-implantation stage embryo, there has been a lot of debate surrounding their use. Further, because embryonic stem cells can only be derived from embryos, it has so far not been possible to make patient-matche.

Currently, two strategies are being used in the development of gene therapies: In the context of gene supplementation, an attempt is made to replace the defective gene with an intact version. However, this is currently only possible for relatively small genes. The second strategy aims to correct disease-causing mutations, but this usually has to be tailored to each individual mutation.

The idea behind gene therapy is very simple: if a disease is caused by a particular version of a single gene, it could be cured by replacing this gene. For example, in cystic fibrosis, a mutation in the gene that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein causes the disease. Replacing it in mucosal cells with a copy that does not carry the mutation could reverse this.

The focal scope of stem cells  that covers wide range of Cellular origin of cancer stem cells ,Genetic constraints, and also epigenetic modifications, that influence growth process and cancer stem cells as therapeutic targets , mathematical models of cancer cell evolution and mechanisms of survival, embryonic Stem Cells, Signaling pathways/factors regulating and/or initiating ESC/iPS cells pluripotency and differentiation , Stem cell transplantation and technologies that will maintain, improve or restore the function of diseased organs, Gene therapies for inherited diseases.
Speakers Interview